Judith Anne Shizuru net worth and biography

Judith Shizuru Biography and Net Worth

Director of Jasper Therapeutics

Dr. Shizuru is a Professor of Medicine (Blood and Marrow Transplantation) and Pediatrics (Stem Cell Transplantation) at Stanford. She is a member of the Stanford Blood and Marrow Transplantation (BMT) faculty, the Stanford Immunology Program, and the Institute for Stem Cell Biology and Regenerative Medicine. She has attended on the BMT clinical service since 1997. Currently, she oversees a research laboratory focused on understanding the cellular and molecular basis of resistance to engraftment of transplanted allogeneic bone marrow cells and the way in which bone marrow grafts modify immune responses.

What is Judith Anne Shizuru's net worth?: The estimated net worth of Judith Anne Shizuru is at least $98.13 thousand as of September 22nd, 2025. Dr. Shizuru owns 156,901 shares of Jasper Therapeutics stock worth more than $98,126 as of September 30th. This net worth evaluation does not reflect any other investments that Dr. Shizuru may own. Learn More about Judith Anne Shizuru's net worth.
How do I contact Judith Anne Shizuru?: The corporate mailing address for Dr. Shizuru and other Jasper Therapeutics executives is 2200 Bridge Pkwy Suite #102, Redwood City, CA, 94065. Jasper Therapeutics can also be reached via phone at 650-549-1400 and via email at [email protected]. Learn More on Judith Anne Shizuru's contact information.
Has Judith Anne Shizuru been buying or selling shares of Jasper Therapeutics?: Judith Anne Shizuru has not been actively trading shares of Jasper Therapeutics during the past quarter. Most recently, on Monday, September 22nd, Judith Anne Shizuru bought 41,000 shares of Jasper Therapeutics stock. The stock was acquired at an average cost of $2.43 per share, with a total value of $99,630.00. Following the completion of the transaction, the director now directly owns 156,901 shares of the company's stock, valued at $381,269.43. Learn More on Judith Anne Shizuru's trading history.
Who are Jasper Therapeutics' active insiders?: Jasper Therapeutics' insider roster includes Jeetinder Mahal (COO), and Judith Shizuru (Director). Learn More on Jasper Therapeutics' active insiders.

Judith Anne Shizuru Insider Trading History at Jasper Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/22/2025	Buy	41,000	$2.43	$99,630.00	156,901

Judith Anne Shizuru Buying and Selling Activity at Jasper Therapeutics

Jasper Therapeutics Company Overview

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Today's Range

Now: $0.63

$0.62

$0.63

50 Day Range

MA: $0.69

$0.57

$0.89

2 Week Range

Now: $0.63

$0.32

$2.69

Volume

2,992 shs

Average Volume

849,337 shs

Market Capitalization

$21.03 million

P/E Ratio

N/A

Dividend Yield